Danaher Co. (NYSE:DHR) Shares Sold by Crewe Advisors LLC

Crewe Advisors LLC cut its position in shares of Danaher Co. (NYSE:DHR) by 30.0% during the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 413 shares of the conglomerate’s stock after selling 177 shares during the quarter. Crewe Advisors LLC’s holdings in Danaher were worth $95,000 as of its most recent filing with the SEC.

Other hedge funds also recently modified their holdings of the company. FMR LLC grew its holdings in shares of Danaher by 15.8% in the 3rd quarter. FMR LLC now owns 23,617,424 shares of the conglomerate’s stock worth $6,566,116,000 after acquiring an additional 3,217,631 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its holdings in shares of Danaher by 3.0% in the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 5,097,986 shares of the conglomerate’s stock worth $1,417,342,000 after acquiring an additional 148,251 shares during the last quarter. Fisher Asset Management LLC grew its holdings in shares of Danaher by 2.6% in the 3rd quarter. Fisher Asset Management LLC now owns 4,552,640 shares of the conglomerate’s stock worth $1,265,725,000 after acquiring an additional 116,299 shares during the last quarter. Massachusetts Financial Services Co. MA grew its holdings in shares of Danaher by 17.6% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 3,582,982 shares of the conglomerate’s stock worth $996,141,000 after acquiring an additional 535,254 shares during the last quarter. Finally, Montrusco Bolton Investments Inc. grew its holdings in shares of Danaher by 0.6% in the 4th quarter. Montrusco Bolton Investments Inc. now owns 1,715,826 shares of the conglomerate’s stock worth $382,936,000 after acquiring an additional 9,942 shares during the last quarter. 79.05% of the stock is currently owned by institutional investors and hedge funds.

Danaher Price Performance

Shares of NYSE:DHR opened at $209.95 on Friday. Danaher Co. has a fifty-two week low of $209.10 and a fifty-two week high of $281.70. The business has a 50-day moving average of $233.96 and a two-hundred day moving average of $252.39. The stock has a market capitalization of $151.64 billion, a P/E ratio of 39.76, a P/E/G ratio of 2.80 and a beta of 0.83. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.40 and a quick ratio of 1.05.

Danaher (NYSE:DHR) last announced its quarterly earnings results on Wednesday, January 29th. The conglomerate reported $2.14 earnings per share for the quarter, hitting analysts’ consensus estimates of $2.14. Danaher had a return on equity of 10.82% and a net margin of 16.33%. During the same period in the previous year, the company earned $2.09 earnings per share. On average, equities research analysts predict that Danaher Co. will post 7.77 EPS for the current fiscal year.

Danaher Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Friday, January 31st. Stockholders of record on Friday, December 27th were paid a $0.27 dividend. The ex-dividend date of this dividend was Friday, December 27th. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.51%. Danaher’s payout ratio is presently 20.45%.

Wall Street Analyst Weigh In

DHR has been the topic of a number of recent research reports. StockNews.com cut Danaher from a “buy” rating to a “hold” rating in a report on Saturday, December 14th. Barclays decreased their target price on Danaher from $275.00 to $240.00 and set an “equal weight” rating for the company in a research report on Thursday, January 30th. Scotiabank assumed coverage on Danaher in a research report on Monday, December 23rd. They issued a “sector perform” rating and a $265.00 target price for the company. TD Cowen raised their target price on Danaher from $310.00 to $315.00 and gave the stock a “buy” rating in a research report on Wednesday, October 23rd. Finally, Jefferies Financial Group decreased their target price on Danaher from $285.00 to $260.00 and set a “buy” rating for the company in a research report on Wednesday, January 29th. Seven research analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $278.00.

Insider Transactions at Danaher

In other news, SVP Brian W. Ellis sold 5,700 shares of Danaher stock in a transaction dated Thursday, January 30th. The stock was sold at an average price of $224.13, for a total value of $1,277,541.00. Following the transaction, the senior vice president now directly owns 20,230 shares in the company, valued at approximately $4,534,149.90. The trade was a 21.98 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 11.10% of the stock is currently owned by corporate insiders.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.